|
gptkbp:instance_of
|
gptkb:monoclonal_antibody
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:Genentech
|
|
gptkbp:activities
|
HE R2 receptor antagonist
|
|
gptkbp:appointed_by
|
intravenous infusion
|
|
gptkbp:approves
|
gptkb:2012
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:trastuzumab
chemotherapy
|
|
gptkbp:clinical_trial
|
Phase III
neoadjuvant therapy
first-line therapy
second-line therapy
HE R2-positive gastric cancer
|
|
gptkbp:contraindication
|
pregnancy
severe heart failure
lactation
hypersensitivity to pertuzumab
concurrent use of anthracyclines
|
|
gptkbp:developed_by
|
gptkb:Genentech
|
|
gptkbp:dosage_form
|
solution for infusion
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Perjeta
|
|
gptkbp:indication
|
metastatic breast cancer
adjuvant treatment
|
|
gptkbp:ingredients
|
gptkb:pertuzumab
C6460 H10080 N1716 O2016 S44
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_atype_of
|
L01 X C13
|
|
gptkbp:is_used_for
|
treatment of breast cancer
treatment of HE R2-positive breast cancer
|
|
gptkbp:manager
|
IV
|
|
gptkbp:manufacturer
|
gptkb:Roche
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
gptkb:brand
|
|
gptkbp:name
|
Essential Medicines
|
|
gptkbp:research_areas
|
gptkb:vaccine
oncology
biologics
targeted therapy
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
nausea
diarrhea
heart problems
thrombocytopenia
infusion-related reactions
neutropenia
hypersensitivity reactions
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:traded_on
|
gptkb:Perjeta
|